A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19

Article activity feed

1. Version published to 10.1038/s41541-021-00352-1

   Jul 22, 2021
2. 

   ScreenIT

   Mar 1, 2021

   SciScore for 10.1101/2021.01.29.428442: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: UTMB is an AAALAC-accredited institution and all animal work was approved by the IACUC Committee of UTMB.
   Randomization	not detected.
   Blinding	The blinded tissue sections were semi-quantitatively scored for pathological lesions using the criteria described in Supplemental Table 1.
   Power Analysis	not detected.
   Sex as a biological variable	Pathogenicity of SARS-CoV-2 in hamsters: On day 0, seven week-old golden Syrian female hamsters (Envigo) were anesthetized with ketamine/xylazine, and 8 animals were exposed intransally to the targeted dose of 105 PFU of SARS-CoV-2 in a volume of 100 μl, while 4 animals were mock-infected with 100 μl 1X DPBS.
   Cell Line …

   SciScore for 10.1101/2021.01.29.428442: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	IACUC: UTMB is an AAALAC-accredited institution and all animal work was approved by the IACUC Committee of UTMB.
   Randomization	not detected.
   Blinding	The blinded tissue sections were semi-quantitatively scored for pathological lesions using the criteria described in Supplemental Table 1.
   Power Analysis	not detected.
   Sex as a biological variable	Pathogenicity of SARS-CoV-2 in hamsters: On day 0, seven week-old golden Syrian female hamsters (Envigo) were anesthetized with ketamine/xylazine, and 8 animals were exposed intransally to the targeted dose of 105 PFU of SARS-CoV-2 in a volume of 100 μl, while 4 animals were mock-infected with 100 μl 1X DPBS.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Antibodies: Monoclonal antibody CR3022 was produced by transient transfection of 293F cells with cDNA expression plasmids obtained from BEI resources.	Antibodies suggested: (Imported from the IEDB Cat# CR3022, RRID:AB_2848080)
   Monoclonal antibodies I1 and I14 against the VSV glycoprotein and monoclonal antibody 23H12 against the VSV matrix protein were purified from hybridoma supernatant by affinity chromatography on Protein G sepharose.	I14 against the VSV glycoprotein suggested: None
   The proteins were transferred to nitrocellulose membrane and probed with polyclonal rabbit serum against SARS-CoV S1 domain (Thermofisher, Cat No. PA5-81798 and PA5-81795), monoclonal antibodies I1 (8G5F11) and I14 (IE9F) against the VSV glycoprotein and monoclonal antibody 23H12 against VSV matrix protein provided by Douglas Lyles (Wake Forest University).	VSV glycoprotein suggested: None
   After washing with DPBS the cells were incubated for 2 hours with monoclonal antibody CR3022 conjugated to Dylight 550 or a mixture of monoclonal antibodies I1 and I14 conjugated to Dylight 488.	I14 suggested: (Rockland Cat# 200-401-I14, RRID:AB_2612206)
   Antibody responses to SARS-CoV-2 spike protein (S1) were measured by an indirect ELISA as described previously(Kurup et al., 2015).	SARS-CoV-2 spike protein ( S1 suggested: None
   The secondary antibodies used in the ELISA are HRP-conjugated goat anti-syrian hamster IgG secondary antibody (Jackson immunoresearch, Cat# 107-035-142, 1:8000 in PBST) or mouse anti-hamster-IgG2/3-HRP (Southern Biotech, Cat# 1935-05, 1:8000 in PBST).	anti-syrian hamster IgG suggested: (Jackson ImmunoResearch Labs Cat# 107-035-142, RRID:AB_2337454) anti-hamster-IgG2/3-HRP suggested: None
   Neutralizing antibody response: Sera collected from animals were tested for neutralizing capabilities against SARS-CoV-2.	SARS-CoV-2 suggested: None
   As the secondary antibody, HRP-labeled goat anti-human IgG (SeraCare) was used at dilution 1:500.	anti-human IgG suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   The recombinant virus was recovered on 293T cells as described previously, filtered through an 0.22 μm filter and used to inoculate Vero (CCL-81, ATCC) or human BEAS-2B lung cells (gift from R. Plemper, University of Georgia).	293T suggested: None BEAS-2B suggested: BCRJ Cat# 0395, RRID:CVCL_0168)
   For immunofluorescence staining, Vero E6 cells were seeded on coverslips and infected at three different MOI ranging from 0.01 to 0.1 PFU.	Vero E6 suggested: RRID:CVCL_XD71)
   To assess viral replication of ConVac in vitro, Vero (CCL-81) cells were seeded in 6-well plates and infected next day at 34°C at an MOI of 5 and 0.05 PFU.	Vero suggested: None
   Software and Algorithms
   Sentences	Resources
   UTMB is an AAALAC-accredited institution and all animal work was approved by the IACUC Committee of UTMB.	UTMB suggested: None
   Data were analyzed with GraphPad Prism (Version 8.4.3) using 4-parameter nonlinear regression.	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.01.29.428442v1 on bioRxiv

   Jan 30, 2021